Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Once-a-Day Lamotrigine Effective for Partial Seizures ST. PAUL, MN -- October 17, 2007 -- The epilepsy drug lamotrigine is effective in controlling partial seizures when taken once a day as an added therapy, according to a study published in the October 16, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology. "These results are important because maintaining stable blood levels of epilepsy drugs and good control of seizures depends on people taking their medications reliably and consistently," said study author Dean Naritoku, MD, of Southern Illinois University in Springfield and member of the American Academy of Neurology. "The more often people have to remember to take their medication each day, the more likely they are to miss a dose. Once-a-day dosing is more convenient for patients." The study involved 239 people from the United States and several other countries. Participants were age 13 and older with partial seizures not fully controlled by medication. Some of the participants also had secondary generalized seizures. The participants were already taking one to two epilepsy medications; lamotrigine was added to their therapy. They received either lamotrigine in an extended-release formula or placebo for 19 weeks. Those taking lamotrigine as an added therapy had 46% fewer partial seizures during the study, compared to 24% fewer for those taking a placebo. In addition, 42% of those taking lamotrigine as an added therapy reduced their seizure frequently by at least half by the end of the study, compared to 24% of those taking a placebo. "This new once daily medication may be an important option for people with epilepsy that could significantly increase their compliance with prescribed treatment," said Naritoku. The most common side effects were headache, which was experienced by 17% of those taking lamotrigine and 15% of those taking placebo, and dizziness, which was experienced by 18% of those taking lamotrigine and five% of those taking placebo. The study was sponsored and conducted by GlaxoSmithKline. SOURCE: American Academy of Neurology E-mail this page to a friend or colleague! To print, use this version